A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation
- 1 December 2010
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 49 (12) , 799-816
- https://doi.org/10.2165/11537850-000000000-00000
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Single- and Multiple-Dose Pharmacokinetics of the Selective Nicotinic Receptor Partial Agonist, Varenicline, in Healthy Japanese Adult SmokersThe Journal of Clinical Pharmacology, 2011
- Pre‐clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependenceBritish Journal of Pharmacology, 2010
- Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of VareniclineDrug Safety, 2010
- Population pharmacokinetic analysis of varenicline in adult smokersBritish Journal of Clinical Pharmacology, 2009
- Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trialThorax, 2008
- Projections of Global Mortality and Burden of Disease from 2002 to 2030PLoS Medicine, 2006
- Principles and Clinical Application of Assessing Alterations in Renal Elimination PathwaysClinical Pharmacokinetics, 2003
- Drug Interactions with Tobacco SmokingClinical Pharmacokinetics, 1999
- Drug Administration in Patients with Renal Insufficiency Minimising Renal and Extrarenal ToxicityDrug Safety, 1997
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976